MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF), a biotechnology company focused on AI-driven voice analytics for drug and alcohol intoxication detection, announced it has appointed Venture Liquidity Providers (VLP), subject to regulatory and final approvals, to provide market-making services aimed at maintaining an orderly trading market for its common shares.
The service will be conducted through W.D. Latimer Co. Ltd. in compliance with Canadian Securities Exchange policies, with MindBio agreeing to pay $5,000 per month over a 12-month term, which may be terminated at any time. Both parties operate at arm’s length and VLP holds no direct or indirect interest in the company or its securities. This engagement is designed to enhance liquidity and ensure a more stable trading environment for shareholders.
MindBio is commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
The market-making agreement comes as MindBio continues to advance its proprietary technology. The company's AI model has significant implications for safety-sensitive industries where impairment detection is critical. By leveraging voice analysis, MindBio aims to provide non-invasive, rapid, and accurate intoxication screening, potentially replacing or supplementing traditional methods such as breathalyzers or blood tests.
For more information on the company and its technology, visit the full press release at https://ibn.fm/4evlA. The appointment of VLP underscores MindBio's commitment to maintaining a liquid and orderly market for its shares, which is essential for investor confidence and the company's growth trajectory.
MindBio Therapeutics is a publicly traded company on the Canadian Securities Exchange under the symbol MBIO, on the Frankfurt Stock Exchange under WF6, and on the OTCQB under MBQIF. The company's advancements in AI-driven voice analytics position it at the forefront of intoxication detection technology, with broad applications across multiple sectors.
